drugset / Trial / NCT00694252

Lapatinib and Circulating Tumor Cells in Breast Cancer

NCT00694252 ↗

Phase 2 Completed 20 enrolled University Hospital of Crete
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy of lapatinib in eradicating chemo- resistant tumour cells circulating in the blood of patients with breast cancer.

Timeline

Start
2008-07
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 1500 mg —

Indications